PulseAugur
EN
LIVE 00:21:09

Anthropic's Claude AI designs protein binders with high success rate · 6 sources tracked

By PulseAugur Editorial · [6 sources] ·

Anthropic has released a technical report detailing how its Claude model was used to design novel protein binders, a crucial step in drug development. The AI model successfully designed binders for 14 out of 15 targets, with a success rate between 22% and 35%, significantly outperforming the typical industry success rate of 10-15%. These designs were independently built and tested by Adaptyv Bio and Twist Bioscience, validating Claude's capabilities in this complex scientific domain. Anthropic also announced plans to launch an access program for scientists to use its most capable models, including Opus 5, for life science research. AI

IMPACT Demonstrates AI's growing capability in complex scientific research, potentially accelerating drug discovery pipelines.

RANK_REASON Research publication detailing AI model's capability in a scientific domain.

Read on X — Anthropic →

AI-generated summary · Google Gemini · from 6 sources. How we write summaries →

Anthropic's Claude AI designs protein binders with high success rate · 6 sources tracked

COVERAGE [6]

  1. X — Anthropic TIER_1 English(EN) · AnthropicAI ·

    We're also publishing a technical report: https://t.co/Ltcqemzn5Z

    We're also publishing a technical report: https://t.co/Ltcqemzn5Z And open-sourcing our prompts and data here: https://t.co/OZXVQWSie2

  2. X — Anthropic TIER_1 English(EN) · AnthropicAI ·

    For more on how Claude ran this experiment and the full results, see our blog: https://t.co/48COrpUcJn

    For more on how Claude ran this experiment and the full results, see our blog: https://t.co/48COrpUcJn

  3. X — Anthropic TIER_1 English(EN) · AnthropicAI ·

    One of our highest priorities remains launching an access program for scientists to use our most capable models. We expect to share more on this soon. Opus 5 re

    One of our highest priorities remains launching an access program for scientists to use our most capable models. We expect to share more on this soon. Opus 5 remains our most capable model available for life science research.

  4. X — Anthropic TIER_1 English(EN) · AnthropicAI ·

    Importantly, protein binders are not drugs. Designing a high-affinity binder is just the first step in the process of developing a drug-like molecule. Even desi

    Importantly, protein binders are not drugs. Designing a high-affinity binder is just the first step in the process of developing a drug-like molecule. Even designing a drug itself is just one phase out of the many required to establish that a drug is safe and effective before

  5. X — Anthropic TIER_1 English(EN) · AnthropicAI ·

    Designing a binder is an easier process than designing a drug, but it’s a useful proxy. The typical success rate in the field today is between 10% and 15%.

    Designing a binder is an easier process than designing a drug, but it’s a useful proxy. The typical success rate in the field today is between 10% and 15%. Between 22% and 35% of Claude's designs bound successfully, depending on the setup. Some of its strongest designs bound htt…

  6. X — Anthropic TIER_1 English(EN) · AnthropicAI ·

    Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is de

    Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per h…

RELATED ENTITIES

RELATED TOPICS